rs639938

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_006946.4(SPTBN2):​c.4899G>A​(p.Leu1633Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0567 in 1,613,912 control chromosomes in the GnomAD database, including 3,203 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.063 ( 379 hom., cov: 32)
Exomes 𝑓: 0.056 ( 2824 hom. )

Consequence

SPTBN2
NM_006946.4 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 3.33

Publications

15 publications found
Variant links:
Genes affected
SPTBN2 (HGNC:11276): (spectrin beta, non-erythrocytic 2) Spectrins are principle components of a cell's membrane-cytoskeleton and are composed of two alpha and two beta spectrin subunits. The protein encoded by this gene (SPTBN2), is called spectrin beta non-erythrocytic 2 or beta-III spectrin. It is related to, but distinct from, the beta-II spectrin gene which is also known as spectrin beta non-erythrocytic 1 (SPTBN1). SPTBN2 regulates the glutamate signaling pathway by stabilizing the glutamate transporter EAAT4 at the surface of the plasma membrane. Mutations in this gene cause a form of spinocerebellar ataxia, SCA5, that is characterized by neurodegeneration, progressive locomotor incoordination, dysarthria, and uncoordinated eye movements. [provided by RefSeq, Dec 2009]
SPTBN2 Gene-Disease associations (from GenCC):
  • autosomal recessive spinocerebellar ataxia 14
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), G2P, Orphanet
  • spinocerebellar ataxia type 5
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.35).
BP6
Variant 11-66693056-C-T is Benign according to our data. Variant chr11-66693056-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 305553.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=3.33 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.107 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SPTBN2NM_006946.4 linkc.4899G>A p.Leu1633Leu synonymous_variant Exon 25 of 38 ENST00000533211.6 NP_008877.2 O15020-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SPTBN2ENST00000533211.6 linkc.4899G>A p.Leu1633Leu synonymous_variant Exon 25 of 38 5 NM_006946.4 ENSP00000432568.1 O15020-1

Frequencies

GnomAD3 genomes
AF:
0.0624
AC:
9499
AN:
152170
Hom.:
374
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0532
Gnomad AMI
AF:
0.00329
Gnomad AMR
AF:
0.0591
Gnomad ASJ
AF:
0.0248
Gnomad EAS
AF:
0.114
Gnomad SAS
AF:
0.0744
Gnomad FIN
AF:
0.146
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0542
Gnomad OTH
AF:
0.0555
GnomAD2 exomes
AF:
0.0678
AC:
17031
AN:
251096
AF XY:
0.0668
show subpopulations
Gnomad AFR exome
AF:
0.0521
Gnomad AMR exome
AF:
0.0571
Gnomad ASJ exome
AF:
0.0250
Gnomad EAS exome
AF:
0.112
Gnomad FIN exome
AF:
0.136
Gnomad NFE exome
AF:
0.0567
Gnomad OTH exome
AF:
0.0644
GnomAD4 exome
AF:
0.0561
AC:
82046
AN:
1461624
Hom.:
2824
Cov.:
33
AF XY:
0.0564
AC XY:
41025
AN XY:
727122
show subpopulations
African (AFR)
AF:
0.0521
AC:
1744
AN:
33480
American (AMR)
AF:
0.0574
AC:
2568
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
0.0264
AC:
689
AN:
26136
East Asian (EAS)
AF:
0.107
AC:
4262
AN:
39700
South Asian (SAS)
AF:
0.0664
AC:
5726
AN:
86254
European-Finnish (FIN)
AF:
0.136
AC:
7224
AN:
53164
Middle Eastern (MID)
AF:
0.0141
AC:
81
AN:
5764
European-Non Finnish (NFE)
AF:
0.0507
AC:
56333
AN:
1112010
Other (OTH)
AF:
0.0566
AC:
3419
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
5592
11183
16775
22366
27958
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2130
4260
6390
8520
10650
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0625
AC:
9522
AN:
152288
Hom.:
379
Cov.:
32
AF XY:
0.0664
AC XY:
4946
AN XY:
74460
show subpopulations
African (AFR)
AF:
0.0533
AC:
2215
AN:
41570
American (AMR)
AF:
0.0599
AC:
917
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.0248
AC:
86
AN:
3470
East Asian (EAS)
AF:
0.114
AC:
592
AN:
5182
South Asian (SAS)
AF:
0.0751
AC:
363
AN:
4832
European-Finnish (FIN)
AF:
0.146
AC:
1546
AN:
10608
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.0542
AC:
3685
AN:
68004
Other (OTH)
AF:
0.0535
AC:
113
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
462
924
1385
1847
2309
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
110
220
330
440
550
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0526
Hom.:
584
Bravo
AF:
0.0539
Asia WGS
AF:
0.125
AC:
433
AN:
3478
EpiCase
AF:
0.0446
EpiControl
AF:
0.0445

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:4
Jul 12, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 01, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 13, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

SPTBN2-related disorder Benign:1
Jul 08, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Autosomal dominant cerebellar ataxia Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.35
CADD
Benign
6.2
DANN
Benign
0.67
PhyloP100
3.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=98/2
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs639938; hg19: chr11-66460527; COSMIC: COSV59447137; COSMIC: COSV59447137; API